Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

Core Insights - Dyne Therapeutics has initiated the Phase 3 HARMONIA trial for zeleciment basivarsen (z-basivarsen) targeting myotonic dystrophy type 1 (DM1) as a confirmatory trial for traditional approval in the U.S. and to support international marketing applications [1][4] Trial Design and Objectives - The HARMONIA trial is a global, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy, safety, and tolerability of z-basivarsen in approximately 150 participants aged 16 and older [2][5] - Participants will receive 6.8 mg/kg of z-basivarsen or placebo every eight weeks for 48 weeks, with a long-term extension available for those completing the placebo-controlled period [5][6] Primary and Secondary Endpoints - The primary endpoint is the change from baseline in the five times sit to stand (5xSTS) test at week 49, which assesses lower extremity strength, balance, and trunk strength [3][6] - Secondary endpoints include video hand opening time, quantitative muscle testing, the 10-Meter Walk/Run test, and the Myotonic Dystrophy Health Index, along with additional patient- and clinician-reported outcomes [3][6] Regulatory Alignment - The trial design and protocol have been aligned with the U.S. Food and Drug Administration (FDA), aiming to support the conversion of Accelerated Approval to traditional approval in the U.S. [4][5] Background on Z-basivarsen - Z-basivarsen is an investigational therapeutic designed to improve functional outcomes in DM1 by reducing toxic nuclear DMPK RNA, facilitating normal mRNA processing [8] - It has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, as well as Orphan Drug designation from the European Medicines Agency (EMA) and Japan's Ministry of Health, Labour and Welfare (MHLW) [8] Context on Myotonic Dystrophy Type 1 - DM1 is a rare, progressive genetic neuromuscular disease affecting approximately 40,000 people in the U.S. and 55,000 in the EU, characterized by a range of debilitating symptoms [9] - The disease is caused by mutations in the DMPK gene, leading to significant RNA splicing disruptions and multi-system manifestations [9] Company Overview - Dyne Therapeutics focuses on developing therapeutics for genetically driven neuromuscular diseases, with ongoing clinical programs for DM1 and Duchenne muscular dystrophy (DMD) [10]